MX2020008359A - Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. - Google Patents
Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.Info
- Publication number
- MX2020008359A MX2020008359A MX2020008359A MX2020008359A MX2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A
- Authority
- MX
- Mexico
- Prior art keywords
- amino
- carboxylic acid
- difluoromethyliden
- meniere
- addiction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628020P | 2018-02-08 | 2018-02-08 | |
| US201862628541P | 2018-02-09 | 2018-02-09 | |
| PCT/US2019/017201 WO2019157273A1 (en) | 2018-02-08 | 2019-02-08 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008359A true MX2020008359A (es) | 2020-11-24 |
Family
ID=67475310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008359A MX2020008359A (es) | 2018-02-08 | 2019-02-08 | Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10653652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3735237A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021512920A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20240154700A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112261938A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019216742B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090258A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276287B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020008359A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019157273A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389001B (es) | 2015-10-23 | 2025-03-20 | Navitor Pharm Inc | Moduladores de interacción de sestrina-gator2 y sus usos. |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| AU2019243586A1 (en) * | 2018-03-29 | 2020-10-15 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
| WO2020086816A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| AU2020376950B2 (en) | 2019-11-01 | 2026-06-11 | Supernus Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| US12678586B1 (en) | 2023-06-12 | 2026-07-14 | John Brundage | Noise injury relief system |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| JP2009517393A (ja) * | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
| CA2790820A1 (en) | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US20130230586A1 (en) * | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| ES2862673T3 (es) * | 2011-12-12 | 2021-10-07 | Zilentin AG | Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo |
| WO2013112363A1 (en) * | 2012-01-27 | 2013-08-01 | Catalyst Pharmaceutical Partners | Method of treating tourette's disorder with gaba-aminotransferase inactivators |
| CN108137484B (zh) * | 2015-10-09 | 2021-02-12 | 西北大学 | 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 |
| KR20240110989A (ko) | 2017-02-08 | 2024-07-16 | 오비드 테라퓨틱스 인크. | 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들 |
-
2019
- 2019-02-08 US US16/270,856 patent/US10653652B2/en active Active
- 2019-02-08 KR KR1020247034793A patent/KR20240154700A/ko not_active Ceased
- 2019-02-08 KR KR1020207025754A patent/KR20210007948A/ko not_active Ceased
- 2019-02-08 AU AU2019216742A patent/AU2019216742B2/en active Active
- 2019-02-08 CN CN201980023215.6A patent/CN112261938A/zh active Pending
- 2019-02-08 KR KR1020257038778A patent/KR20250167147A/ko active Pending
- 2019-02-08 EP EP19750667.8A patent/EP3735237A4/en active Pending
- 2019-02-08 CA CA3090258A patent/CA3090258A1/en active Pending
- 2019-02-08 WO PCT/US2019/017201 patent/WO2019157273A1/en not_active Ceased
- 2019-02-08 MX MX2020008359A patent/MX2020008359A/es unknown
- 2019-02-08 JP JP2020542858A patent/JP2021512920A/ja active Pending
- 2019-02-08 IL IL276287A patent/IL276287B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240154700A (ko) | 2024-10-25 |
| JP2021512920A (ja) | 2021-05-20 |
| KR20250167147A (ko) | 2025-11-28 |
| WO2019157273A1 (en) | 2019-08-15 |
| CN112261938A (zh) | 2021-01-22 |
| CA3090258A1 (en) | 2019-08-15 |
| US20190240174A1 (en) | 2019-08-08 |
| KR20210007948A (ko) | 2021-01-20 |
| EP3735237A4 (en) | 2021-03-17 |
| EP3735237A1 (en) | 2020-11-11 |
| AU2019216742A1 (en) | 2020-08-13 |
| IL276287B1 (en) | 2026-07-01 |
| IL276287A (en) | 2020-09-30 |
| AU2019216742B2 (en) | 2024-05-09 |
| US10653652B2 (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009190A (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| MX2022000143A (es) | Metodos novedosos. | |
| DOP2017000272A (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| MX383932B (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue. | |
| ECSP21031200A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CL2018000811A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| MX2022003128A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
| IL276287A (en) | Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of buzzing, Sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD and addiction | |
| CO2018005983A2 (es) | Compuestos de isoindol | |
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| MX394475B (es) | Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes. | |
| MY179105A (en) | Methods of treating alzheimer's disease | |
| CL2019001918A1 (es) | Métodos para tratar infecciones bacterianas. | |
| MX2020009999A (es) | Composiciones farmacéuticas para inhibir citocinas inflamatorias. | |
| MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| MX2021011598A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| MX2018013943A (es) | Metodo de tratamiento de hiperglucemia. |